| Angioedemas, Hereditary
Takhzyro vs Berinert
Side-by-side clinical, coverage, and cost comparison for angioedemas, hereditary.Deep comparison between: Takhzyro vs Berinert with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBerinert has a higher rate of injection site reactions vs Takhzyro based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Berinert but not Takhzyro, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Takhzyro
Berinert
At A Glance
SC injection
Every 2-4 weeks
Plasma kallikrein inhibitor
IV injection
C1 esterase inhibitor
Indications
- Angioedemas, Hereditary
- Angioedemas, Hereditary
Dosing
Angioedemas, Hereditary (adults and pediatric >=12 years) 300 mg SC every 2 weeks; every 4 weeks may be considered if well-controlled (e.g., attack free) for more than 6 months.
Angioedemas, Hereditary (pediatric 6 to <12 years) 150 mg SC every 2 weeks; every 4 weeks may be considered if well-controlled (e.g., attack free) for more than 6 months.
Angioedemas, Hereditary (pediatric 2 to <6 years) 150 mg SC every 4 weeks.
Angioedemas, Hereditary 20 IU/kg body weight by slow intravenous injection; doses lower than 20 IU/kg body weight should not be administered.
Contraindications
—
- Life-threatening hypersensitivity reactions, including anaphylaxis, to C1 esterase inhibitor preparations
Adverse Reactions
Most common (>=10%) Injection site reactions, upper respiratory infections, headache, rash, dizziness, diarrhea, myalgia.
Less common Hypersensitivity, increased aspartate transaminase, increased alanine transaminase.
Most common (>4%) Dysgeusia
Serious Laryngeal edema, facial HAE attacks with laryngeal edema, swelling, exacerbation of hereditary angioedema, laryngospasm
Postmarketing Hypersensitivity/anaphylactic reactions, injection-site pain, injection-site redness, chills, fever, thromboembolism (including basilar artery thrombosis, pulmonary microemboli)
Pharmacology
Plasma kallikrein inhibitor; lanadelumab-flyo is a fully human IgG1/kappa monoclonal antibody that binds and inhibits plasma kallikrein, reducing cleavage of high-molecular-weight kininogen and excess bradykinin generation that causes increased vascular permeability and angioedema attacks in HAE patients with C1-inhibitor deficiency or dysfunction.
C1 esterase inhibitor is a plasma-derived serine protease inhibitor (serpin) that inhibits C1r, C1s, factor XIIa, kallikrein, and factor XIa, regulating the complement, contact (intrinsic coagulation), fibrinolytic, and coagulation cascades; IV replacement in C1-INH-deficient HAE patients suppresses bradykinin generation and reduces vascular permeability.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Takhzyro
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Berinert
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Takhzyro
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (1/8)
Berinert
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (3/8) · Qty limit (0/8)
Humana
Takhzyro
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Berinert
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TakhzyroView full Takhzyro profile
BerinertView full Berinert profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.